Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果

Core Insights - Apollomics Inc. announced the results of a Phase III clinical trial for uproleselan, which is aimed at treating acute myeloid leukemia (AML) [1] - The trial showed that uproleselan improved overall survival (OS) compared to the control group, with a median OS of 9.3 months for the uproleselan group versus 14.3 months for the control group [1] - The company plans to submit a New Drug Application (NDA) for uproleselan in August 2024, with estimated costs for the trial reaching $50 million [1] Group 1: Clinical Trial Results - Uproleselan demonstrated a median overall survival (OS) of 9.3 months in the treatment group compared to 14.3 months in the control group [1] - The trial involved 69 patients in the uproleselan group and 71 in the control group, with a p-value of 0.48 indicating no significant difference in OS [1] - The treatment showed a 43$50 million [1] - The company is actively preparing for the submission and is optimistic about the trial results [1]